Reduced nodal burden based on tumour subtype can help tailor axillary treatment in breast cancer patients who have undergone neoadjuvant chemotherapy

Research output: Other contribution (Published)Other contribution

Original languageEnglish (Ireland)
Media of outputOther Item
Volume104
Publication statusPublished - 1 Apr 2017

Cite this